Celldex Therapeutics, Inc (NASDAQ: CLDX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT CELLDEX THERAPEUTICS, INC

Celldex Therapeutics, Inc (NASDAQ: CLDX)
Listen to this Section


$31.49
+0.2150 ( +0.69% ) 402.0K

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Clinical Trial Pipeline Stages


Drug Name Stage
Barzolvolimab (CDX-0159) (KIT receptor)DetailsKIT/Mast cell diseases, Chronic spontaneous urticaria, Chronic urticaria Phase 3
Barzolvolimab (CDX-0159)DetailsChronic inducible urticaria Phase 3
Barzolvolimab (CDX-0159) (KIT receptor)DetailsPrurigo nodularis, Skin disease/disorder Phase 2
Barzolvolimab (CDX-0159)DetailsEosinophilic Gastritis, Eosinophilic Esophagitis Phase 2
Barzolvolimab (CDX-0159) (KIT receptor)DetailsSkin disease/disorder, Atopic dermatitis Phase 2
CDX-585DetailsSolid tumor/s, Cancer Phase 1
CDX-622DetailsInflammatory disease Phase 1
CDX-527 (and PD-L1 / CD27)DetailsSolid tumor/s, Cancer Failed
CDX-1140 (CD40 agonist)DetailsSolid tumor/s, Cancer, Diffuse large B cell lymphoma Failed

Market Data


Open $31.49
Previous Close $31.27
Volume 402.0K
Market Cap $2.45B
Day Range $30.86 - $32.11
52 Week Range $19.52 - $35.79
Shares Outstanding 78.49M
Change % +0.69%
Net Change ▲ 0.2150
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
IPO Year1986
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: 11,500.00

Date Type Amount Purchased Purchaser
2024-11-12 Buy 11500.00 Marucci Anthony S

SEC Filings


Form Type Description Pages Date
3 Insider transactions 2 Nov 12, 2025
4 Insider transactions 1 Nov 12, 2025
8-k 8K-related 14 Nov 10, 2025
10-q Quarterly Reports 70 Nov 10, 2025
8-k 8K-related 14 Aug 19, 2025
4 Insider transactions 1 Aug 15, 2025
8-k 8K-related 14 Aug 07, 2025
10-q Quarterly Reports 69 Aug 07, 2025
4 Insider transactions 1 Jun 09, 2025
4 Insider transactions 1 Jun 09, 2025

Latest News


× Before browsing our site, please accept our cookies policy